title: Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade.
authors.forename: C G
authors.initials: CG
authors.lastname: ter Meulen
authors.forename: C C
authors.initials: CC
authors.lastname: Baan
authors.forename: R J
authors.initials: RJ
authors.lastname: Hené
authors.forename: L B
authors.initials: LB
authors.lastname: Hilbrands
authors.forename: A J
authors.initials: AJ
authors.lastname: Hoitsma
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000037:antagonists & inhibitors*; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab